Global optical semiconductor device leader Seoul Viosys announced that its 2024 annual revenue reached KRW 695 billion, marking a 37.9% increase from 2023's revenue of KRW 504 billion.
HK inno.N's new drug for gastroesophageal reflux disease, K-Cab, is expected to enter the Australian and New Zealand markets, leading to expectations for good performance.
Nature Republic has surpassed ¥4.7 billion (approximately KRW 43.6 billion) in cumulative supply sales in Japan within just three years, driven by its offline-focused market strategy.
At the end of last year, household loans from the five major commercial banks increased by nearly KRW 800 billion, while corporate loans decreased by nearly KRW 9 trillion.